Kovitz Investment Group Partners LLC Acquires New Shares in argenex SE $ARGX

Key Points

• Kovitz Investment Group Partners LLC has acquired a new stake in argenex SE, purchasing 1,347 shares valued at approximately $797,000 in the first quarter.
• The company reported $3.74 earnings per share for the last quarter, exceeding the consensus estimate of $2.84, with revenues reaching $866.79 million.
• Wall Street analysts have set a consensus price target of $746.81 for argenex stock, with multiple firms assigning a "buy" rating.

Kovitz Investment Group Partners LLC acquired a new stake in argenex SE (NASDAQ:ARGX - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 1,347 shares of the company's stock, valued at approximately $797,000.

Several other institutional investors and hedge funds have also modified their holdings of ARGX. Mariner LLC lifted its stake in shares of argenex by 15.9% in the 4th quarter. Mariner LLC now owns 3,711 shares of the company's stock valued at $2,283,000 after purchasing an additional 509 shares during the last quarter. GeoWealth Management LLC lifted its stake in shares of argenex by 56.3% in the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock valued at $31,000 after purchasing an additional 18 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of argenex by 21.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 24,929 shares of the company's stock valued at $15,332,000 after purchasing an additional 4,445 shares during the last quarter. MML Investors Services LLC lifted its stake in shares of argenex by 1.7% in the 4th quarter. MML Investors Services LLC now owns 8,844 shares of the company's stock valued at $5,439,000 after purchasing an additional 145 shares during the last quarter. Finally, Stifel Financial Corp lifted its stake in shares of argenex by 6.8% in the 4th quarter. Stifel Financial Corp now owns 9,433 shares of the company's stock valued at $5,801,000 after purchasing an additional 601 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company's stock.

argenex Stock Performance

NASDAQ:ARGX opened at $660.97 on Thursday. The firm's 50-day moving average is $592.00 and its 200-day moving average is $597.99. argenex SE has a 52-week low of $510.05 and a 52-week high of $696.21. The company has a market cap of $40.45 billion, a price-to-earnings ratio of 33.90, a PEG ratio of 0.76 and a beta of 0.39.

argenex (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $3.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.84 by $0.90. argenex had a net margin of 40.98% and a return on equity of 21.06%. The company had revenue of $866.79 million for the quarter, compared to the consensus estimate of $776.82 million. Equities analysts predict that argenex SE will post 3.13 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ARGX. HC Wainwright lifted their price objective on shares of argenex from $720.00 to $774.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Morgan Stanley lifted their target price on shares of argenex from $700.00 to $766.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Wells Fargo & Company lifted their target price on shares of argenex from $741.00 to $756.00 and gave the stock an "overweight" rating in a report on Thursday, July 31st. Citigroup reiterated a "buy" rating on shares of argenex in a report on Wednesday, May 21st. Finally, JMP Securities set a $699.00 target price on shares of argenex in a report on Wednesday, May 14th. Two investment analysts have rated the stock with a Strong Buy rating and eighteen have assigned a Buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $746.81.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.